Kym Denny, Chief Executive Officer (and PLC Board Director)
Kym Denny has been CEO of hVIVO (formerly Retroscreen Virology), a specialty respiratory biopharma company, since 2010. Kym led the Company’s highly successful IPO on AIM in 2012, and has since led several successful fund raising drives totaling almost £100M.
Kym strengthened the financial performance of hVIVO from a turnover of £1m in the 6 month period ending 31 December 2010, to £14.39m (2012), £27.5m (2013) and £18.5m (2014), and has since ensured that the company’s performance is maintained through solid growth and investment in R&D. In addition, Kym has been leading hVIVO to implement efficient business practices resulting in profit margins increasing from 14.4% (2011) to 29.4% (2014).
Kym has extensive drug development leadership experience in therapeutic areas including Infectious Disease, Respiratory, CNS, oncology, women’s health and orphan indications. She was VP of Clinical Research at SRA International, MD at Harrison Clinical Research, Board member responsible for Clinical Operations at Profiad, and Founder and President at Insite Clinical Trials.
In 2016, Kym was the Ernst & Young (EY) Entrepreneur of the Year UK category winner for Healthcare, won the Gold Award in the “Female Executive of the Year in Europe, the Middle East and Africa” category at the at the Women in Business Stevie Awards, and was appointed to the Mayor of London’s Business Advisory Board.
John Efthimiou, Executive Vice President, Translational Medicine
John joined hVIVO as Executive Vice President, Translational Medicine in October 2015. He is a physician and accredited respiratory specialist with over 15 years of broad clinical experience in the care of patients with respiratory and infectious diseases, cardiology, rheumatology and general medicine in London and Oxford teaching hospitals.
Subsequent to his successful clinical career, he has had over 25 years broad Research and Development and Clinical Development leadership experience with major pharmaceutical companies (GSK, Novartis, Roche/Chugai, Alimirall), as well with small pharma and biotech companies to CMO/Board level positions. He has been involved in the successful development, regulatory approval and commercialisation of over 100 new medicines particularly in the areas of respiratory, allergy, infectious diseases, rheumatology, inflammation, metabolic/endocrine and cardiovascular diseases.
John gained a BSc (1st Class Hons) in Biochemistry and MB, BS medical degrees from Guy’s/University of London and was later awarded a MD from the University of London and appointed FRCP by the Royal College Physicians, London. His major research and development interests have been in asthma, COPD, cystic fibrosis, allergic, bacterial and viral infectious disorders and in developing novel biomarkers and therapies to manage these. In recent years he has also developed an interest in medical communications, patient and doctor lexicons, and in enhancing patient-doctor dialogue and adherence.
Chris Poll, Executive Vice President, Research & Development
Chris joined hVIVO (formerly Retroscreen Virology) as Vice President, Research and Development Operations in August 2013 and was promoted to Executive Vice President, Research and Development in January 2015.
He has over 28 years research and research leadership experience in drug discovery with major pharmaceutical companies (Glaxo, Sandoz, Bayer, Novartis) in the areas of respiratory disease, inflammation and immunology research.
Prior to joining hVIVO Chris was Executive Director and Head of COPD Research at Novartis Institutes for Biomedical Research where he was responsible for a portfolio of COPD projects from exploratory activities up to the selection of candidates for proof of concept clinical studies. Before joining Novartis he was Head of the Respiratory Pharmacology Department at Bayer.
Chris gained a BSc (Hons) degree in Physiology and Biochemistry from the University of Southampton in 1980 and received his PhD from the University of London in 1986 studying the role of calcium in stimulus-response coupling in human platelets. He is also an honorary senior lecturer in the airway disease section of the National Heart and Lung Institute, Imperial College, London.
Reid Tripp, Executive Vice President, Business Development & Marketing
Reid has more than 25 years of international experience within the life science industry and has an MBA.
Before joining hVIVO, he held senior management business development and marketing positions with various large , mid-sized and small global Clinical Research Organisations where he successfully built and managed sales , marketing, proposals and contracts teams, delivered hundreds of millions in contractual relationships and overall, enhanced customer satisfaction. Reid has also served in a senior management role at a start-up biotechnology company and has held various management positions for a large pharmaceutical company.
Liam Eves, Executive Vice President, Humatics
Dedicated to tackling the inefficiencies within the clinical trial and pharma industries, Liam joined hVIVO (formerly Retroscreen Virology) in 2011 as Associate Director of Volunteer Recruitment. Before serving as Executive VP Humatics, he was Head of the Volunteer Screening Division responsible for overseeing the opening of 2 additional screening centres in Cambridgeshire and Manchester, contacting over 140,000 volunteers and increasing the number of subjects screened by approximately 1500% whilst increasing efficiencies by 700% in 2013 and maintaining a 97% recruitment delivery track record.
The Humatics division is focussed on the data generated from the samples and information from our volunteers involved in any specific research study. From volunteer appeal and recruitment, data capture, to storage, and data analytics, this is a key engine room for the rich and mineable information we derive from our human samples.
Liam’s early career as a professional footballer was cut short due to injury which motivated Liam to pursue a Bachelor’s in Neuropsychology. Immediately prior to joining hVIVO, Liam worked as an independent patient recruitment consultant, with expertise in site optimisation and centralised patient recruitment strategies. Liam is a former special interest board member at The Institute of Clinical Research for patient recruitment, and a visiting lecturer at the University of Central Lancashire.
Graham Yeatman, Chief Financial & Business Officer (and PLC Board Director)
Graham joined hVIVO Services Limited (formerly Retroscreen Virology Limited) as Finance Director in May 2011 and became Finance Director of hVIVO plc (formerly Retroscreen Virology Group plc) in April 2012. Graham was promoted to Chief Financial and Business Officer in January 2015.
Graham has significant experience of building businesses for rapid growth and profitability. He is a Chartered Accountant and trained and worked with PricewaterhouseCoopers for thirteen years across its audit, tax, consultancy, business process reengineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. In 2006 he joined Neuropharm Group plc as Chief Financial Officer. Graham has a First in Economics and Maths from Bristol University.